RecruitingPhase 2Phase 3NCT06279130

Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations

Sponsor

The Netherlands Cancer Institute

Enrollment

133 participants

Start Date

Jan 29, 2024

Study Type

INTERVENTIONAL

Conditions

Resectable MMR-deficient Solid Tumors Resectable MMR-proficient Solid Tumors

Summary

In this study, the efficacy of botensilimab and balstilimab in mismatch repair deficient (dMMR) and mismatch repair proficient (pMMR) tumors will be assessed.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel), a drug called balstilimab, and others for people with resectable mmr-deficient solid tumors and resectable mmr-proficient solid tumors. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGbotensilimab

Anti cytotoxic T-lymphocyte associated protein-4 (anti-CTLA4)

DRUGbalstilimab

Anti programmed cell death protein-1 (anti-PD1)

DRUGFLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)

5-Fluorouracil (2400mg/m2), leucovorin (200mg/m2), oxaliplatin (85mg/m2), docetaxel (50mg/m2).

Locations(1)

The Netherlands Cancer Institute

Amsterdam, North Holland, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06279130